Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).
Stemler J, Yeghiazaryan L, Stephan C, Mohn KG, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockienė B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium. Stemler J, et al. Among authors: neuhann jm. Int J Infect Dis. 2024 Sep;146:107161. doi: 10.1016/j.ijid.2024.107161. Epub 2024 Jul 9. Int J Infect Dis. 2024. PMID: 38992789 Free article. Clinical Trial.
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).
Neuhann JM, Stemler J, Carcas AJ, Frías-Iniesta J, Akova M, Bethe U, Heringer S, Salmanton-García J, Tischmann L, Zarrouk M, Cüppers A, Grothe J, Leon AG, Mallon P, Negi R, Gaillard C, Saini G, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Yeghiazaryan L, Posch M, Koehler P, Cornely OA. Neuhann JM, et al. Vaccine. 2023 Nov 22;41(48):7166-7175. doi: 10.1016/j.vaccine.2023.10.029. Epub 2023 Oct 31. Vaccine. 2023. PMID: 37919141 Free article. Clinical Trial.
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
Neuhann JM, Stemler J, Carcas A, Frías-Iniesta J, Bethe U, Heringer S, Tischmann L, Zarrouk M, Cüppers A, König F, Posch M, Cornely OA. Neuhann JM, et al. Trials. 2022 Oct 8;23(1):865. doi: 10.1186/s13063-022-06791-y. Trials. 2022. PMID: 36209129 Free PMC article.